Abstract: Concentrative nucleoside transporters (CNT; SLC28) and equilibrative nucleoside transporters (ENT; SLC29) mediate the uptake of natural nucleosides and a variety of nucleoside-derived drugs, mostly used in anticancer therapy. SLC28 and SLC29 families consist in three and four members, respectively, which differ in their substrate selectivity and their energy requirements. Tissue distribution of these transporters is not homogeneous among tissues, and their expression can be regulated. In epithelia, CNT and ENT proteins are mostly localized in the apical and basolateral membranes, respectively, which results in nucleoside and nucleoside-derived drugs vectorial flux. Nucleoside transporters can play physiological roles other than salvages, such as the modulation of extracellular and intracellular adenosine concentrations. Moreover, these transporters also have clinical significance. ENT proteins are target of dipyridamole and dilazep, used as vasodilatory drugs in the treatment of heart and vascular diseases. On the other hand, nucleoside transporters are responsible for the cellular uptake of currently used anticancer nucleoside-derived drugs, thus these membrane proteins might play a significant role in nucleoside-based chemotherapy. Finally, several polymorphisms have been described in CNT and ENT proteins that could affect nucleoside homeostasis, adenosine signalling events or nucleoside-derived drug cytotoxicity or pharmacokinetics.
INTRODUCTION
Nucleosides play an important role as metabolic precursors in nucleic acid synthesis being crucial for the control of cell and tissue growth. In addition, nucleosides and nucleotides are also key determinants of energy metabolism (ATP, GTP), ligands of purinergic receptors (adenosine, inosine) or transducers of endocrine signals (cAMP, cGMP), thereby modulating a wide range of cellular events. Moreover, many nucleoside analogues are currently used in anticancer and antiviral therapies, thus highlighting the pharmacological role these molecules can also play in disease.
De novo synthesis of purine and pyrimidine nucleotides is energetically costly and is restricted to selected cell types, thus, nucleoside salvage and recycling are common events. Moreover, since these molecules are hydrophilic, their efficient transport across the plasma membrane requires a mediated process which is facilitated by specific membrane proteins.
NUCLEOSIDE TRANSPORTERS
Two gene families have been identified as responsible for the uptake of natural nucleosides in mammals: Solute Carrier families 28 and 29 (SLC28 and SLC29). The former encodes CNT (Concentrative Nucleoside Transporter) proteins, which mediate a unidirectional sodium-dependent transport and consists of three members: CNT1, CNT2 and CNT3 [1] .
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Equilibrative Nucleoside Transporters
Since they catalyse a passive diffusion process, equilibrative transporters are bidirectional carriers, mediating the influx and efflux of substrates. The two well-characterized transporters hENT1 and hENT2 have lower affinities for natural nucleosides than concentrative transporters, with values in the high micromolar range (100-800 μM), but with a wide selectivity of substrates, accepting most purines and pirimidines (Table 1) [3, 4] . Moreover, hENT2 is also able to transport a wide range of purine and pyrimidine nucleobases [5] . hENT1 and hENT2 also differ in their sensitivity to inhibition by the nucleoside analogue nitrobenzylthioinosine (NBTI) (with IC 50 values of 0.4 nM and 2800 nM, respectively). Moreover, although both systems are the natural targets of vasodilation potentiators such as dipyridamole, dilazep and draflazine, hENT1 is 100 to 1000-fold more sensitive than hENT2 [6] .
The two new members of the SLC29 gene family have been identified recently. hENT3 is a 475 amino acid protein 29% identical in sequence to hENT1, with a very long hydrophilic N-terminus which contains two (DE)XXXL(LI) dileucine endosomal/lysosomal targeting motifs [7] . hENT3 is a lysosomal pH-dependent transporter, and the optimum pH value of 5.5 probably reflected the location of the transporter in acidic, intracellular compartments. The protein has broad substrate selectivity and can also transport adenine, however, it is relatively insensitive to the classical equilibra-tive nucleoside transporters inhibitors NBTI, dilazep or dipyridamole ( Table 1 ) [8] . The fourth member of the SLC29 family, ENT4/PMAT is a protein of 530 residues, functionally quite distant from the rest of the members of the family [1] . It was originally described as a monoamine/organic transporter (PMAT), however it presents some capability of transporting adenosine at acidic pH but not a pH 7.4, and is only weakly inhibited by the classical inhibitors of equilibrative nucleoside transporters ( Table 1 ) [9] .
ENT transporters share a proposed topological structure composed of 11 transmembrane domains, with an intracellular amino terminus and an extracellular carboxy terminus [10] . Studies of different human and rat ENTs show that the region between transmembrane domains 3 and 6 contains residues responsible for both sensitivity and resistance to NBTI, as well as coronary vasodilators [10, 11] . Regarding substrate selectivity, transmembrane domains 1 and 6 in hENT2 contribute to the ability to transport deoxynucleosides, while transmembrane domains 5 and 6 are involved in nucleobase recognition [4, 12] .
Concentrative Nucleoside Transporters
CNTs mediate the unidirectional flow of nucleosides in an active, energy costly process coupled to the transmembrane sodium gradient. They show a high affinity for their substrates (most are in the low micromolar range, 10-100 μM), but are more selective for them than equilibrative transporters ( Table 1) [2] . Thus, although all accept uridine as a permeant, they differ functionally with respect to their selectivities for other permeants. hCNT1 is the pyrimidinenucleoside preferring transporter and although adenosine binds the translocation site of the transporter with relative high affinity (Kd 14 M) it does not translocate it [13] . hCNT2 is a purine-nucleoside preferring transporter, although it also transports uridine, whereas hCNT3 shows much broader selectivity, translocating both purine and pyrimidine nucleosides.
Stoichiometry in the translocation process mediated by CNT proteins might determine the intracellular nucleoside concentrations for efficient phosphorylation, since coupling with either one or two sodium ions would dramatically modify, at least theoretically, the concentrative capacity of the transporter. hCNT1 and hCNT2 are supposed to show a 1:1 (nucleoside:sodium) stoichiometry [14, 15] , whereas hCNT3 is believed to translocate two sodiums per nucleoside being transported [16] . Moreover, while hCNT1 and hCNT2 are strictly Na + -nucleoside cotransporters, hCNT3 exhibits pHdependent nucleoside transport, but with a 1:1 stoichiometry in the presence of H + alone [17] .
Protein chimera and site-directed mutagenesis studies has been used extensively to determine the molecular mechanisms involved in substrate recognition and translocation of the CNTs [18] [19] [20] . The three members of the SLC28 gene family share a probable topology of 13 transmembrane domains, with an extracellular carboxy terminus and with the cation and substrate recognition sites in the carboxy half of the protein.
TISSUE DISTRIBUTION AND CELLULAR LOCALI-ZATION
Equilibrative nucleoside transporters, particularly ENT1, may be considered ubiquitous transporters, with significant variability in tissue abundance. High expression of hENT1 protein or mRNA has been demonstrated in many tissues including erythrocytes, vascular endothelium, placenta, brain, heart, liver or colon [21] . ENT2 is expressed in a wide range of tissues, including the vascular endothelium, heart, brain, placenta, thymus, pancreas, prostate and kidney, with particularly high expression in skeletal muscle [3, 22] . hENT3 is widely expressed in human tissues but is particular abundant in placenta, from which tissue the cDNA was originally cloned [8] . hENT4 is likely to be ubiquitously expressed in human tissues. It is especially abundant in the heart, in particular in ventricular myocytes and vascular endothelial cells but is virtually absent from the sinoatrial and atrioventricular nodes [9] . Concentrative nucleoside transporters were initially thought to be expressed mostly in (re)absorptive epithelia, but now they are known to be broadly present in the body. Active transport is found particularly in specialized epithelial tissues such as small intestine, kidney and liver, where CNT1 is particularly abundant [21, 23, 24] . The expression of CNT2 in immune system cells is ubiquitous but highly variable [21] . However, CNT3 levels are low in lymphoid cells and high in monocytes and macrophages, whereas, CNT1 is virtually absent in most of the immune system cells and it only has been detected in mouse bone marrow macrophages [25, 26] . In brain, CNT1 and CNT3 have been detected in some regions [16, 27] , whereas CNT2 is widespread, although most prevalent in the amygdala, the hippocampus, specific neocortical regions and the cerebellum [28] . In fact, this distribution partially overlaps that of ENT1 and is similar to that of the A1 type receptor. CNTs have also been identified in endothelial cells, although they have a minimal contribution to nucleoside transport compared with ENTs [29] .
Therefore, tissue distribution of nucleoside transporters (NTs) shows mammalian cells express more than one type of NT proteins, often combining members of both gene families, CNT and ENT, in a single cell type. The physiological rationale for the co-expression of several NT proteins is still a matter of controversy, except in selected epithelial cells, in which CNT and ENT proteins are localized at the different polarized domains, allowing the nucleoside vectorial flux across epithelial barriers.
Several studies using fluorescently tagged transporters have demonstrated that concentrative transporters seem to be restricted to the apical membrane of polarized epithelial cells [30] [31] [32] . However, there remains some controversy about the localization of equilibrative transporters. hENT2 seems restricted to the basolateral domain [33] , whereas ENT4 is located in the apical membrane [9] . hENT1 was described to be mainly localized in the basolateral membrane, although it can also be detected in the apical domain [33, 34] . Additionally, basolateral targeting motifs have been identified for hENT1 and hENT2 of cultured polarized kidney epithelial cells [33] , and trafficking of hCNTs to apical membranes appears to be independent of glycosilation status [35] . Moreover the recent identification of a novel hCNT transporter, particularly a hCNT3 variant lacking the first 69 amino acids of the N-terminus tail and retained at the endoplasmic reticulum (ER), supports the view that ER export motifs reside in this domain [36] .
The asymmetric distribution of CNTs and ENTs in apical and basolateral membranes of epithelial cells, respectively, results in vectorial fluxes of nucleosides from the lumen to the interstitial space across epithelia [32, 34] . This putative role of nucleoside transporters in the absorption/reabsorption processes is supported by its localization along both the intestinal tract and the renal tubule. In the former sodiumdependent nucleoside transport follows a proximal-to-distal gradient [37, 38] . Whereas in the latter, the three CNT transporters are expressed in the proximal convoluted and straight tubule (PCT and PST) [39] , segments that are implicated in (re)absorption of other metabolites [40, 41] . Interestingly, adenosine transporters CNT2 and CNT3 are also expressed in the glomerulus and in the distal segments of the rat nephron [39] , localization that would be consistent with a putative role of these proteins in the regulation of tubular adenosine levels [42] .
The vectorial (re)absorption of nucleosides and their derivatives can contribute to whole body nucleoside homeostasis, and probably, to nucleoside-derived drugs pharmacokinetics. For this reason, there is an increasing interest in the search for nucleoside transporter expression, particularly for CNT-type proteins, in other epithelial barriers and in highly specialized tissues in which nucleoside provision can be essential. Primary cultures of rat brain endothelial cells and rat choroid plexus epithelial cells present a polarized sodiumdependent adenosine uptake, apparently at the surfaces facing the interstitial and cerebrospinal fluids respectively [43] . The functional and molecular characterization of NTs in the blood-retinal barrier has also been recently addressed by analyzing a rat immortalized retinal capillary endothelial cell line [44] . The results showed that although the cell line expresses CNT2 and CNT3 related-mRNA, ENT2 mediates most of the adenosine transport at the inner blood-retinal barrier. Another physiological barrier with presumed high nucleoside and nucleobase needs is the blood-testis barrier. The whole panel of plasma membrane NTs is present in primary cultures of Sertoli cells (ENT1, ENT2, CNT1, CNT2, and CNT3), whereas a sodium-coupled activity has been identified in these cultures, thus providing a first evidence for a combined role of ENTs and CNTs in supplying nucleosides for spermatogenesis [45] . Chorionic villi sections of human term placenta express mRNAs and proteins for hENT1 and hENT2 but only mRNA for hCNT2. Immunolocalization studies showed presence of hENT1 in the brushborder membrane of the syncytiotrophoblasts [46] . This broad distribution of NTs anticipates a major role of these membrane proteins in the regulation of nucleoside homeostasis, the adenosine levels or in the pharmacokinetics of most nucleoside-derived drugs used in anticancer and antiviral therapies. In fact, tissue-specific regulation of NTs rather than distribution alone can probably add some valuable information about NT biology and pharmacology.
REGULATION OF NUCLEOSIDE TRANSPORTERS
NTs show different regulatory properties, suggesting complementary physiological roles for these membrane proteins, which would explain the coexpression of several NT, at least in highly differentiated cell types. Most of regulation studies suggest that ENT1 plays a role in proliferation, being responsible for constitutive nucleoside supply, whereas CNT expression is probably linked to cell differentiation. In murine bone marrow macrophages, proliferation induced by MCSF results in the up-regulation of ENT1. Moreover, blocking ENT1 function inhibits proliferation and significantly reduces the incorporation of extracellular thymidine into DNA [26] . In contrast, macrophage activation by IFN-or promotion of apoptosis by LPS and TNF-block proliferation and up-regulation of ENT1 induced by MCSF, while produce an increase in CNT1 and CNT2 activity [26, 47] . Similarly, in intestinal cells mitogenic agents and epithelial wounding increase ENT1 activity, whereas induction of differentiation by glucocorticoids regulates expression of CNT2 [48] . The idea that ENT1 is a major provider of nucleosides for DNA synthesis and cell proliferation is also supported by the evidence that it is highly expressed and abundant in tumours, whereas concentrative transporter expression, such as CNT1, is more easily lost during transformation [49] .
NTs, except CNT1, are adenosine transporters, thus they could also play a role in the modulation of extracellular and intracellular adenosine concentrations. In fact, as indicated above, in some tissues distribution of some NTs is similar to that of adenosine receptors. The possibility that a transporter protein could modulate extracellular adenosine levels has been comprehensively addressed in endothelial cells and in neurons, but has been mostly, if not exclusively, focused on ENT1 ( [50, 51] and reviewed elsewhere in this issue). However, CNT2 is a sodium-coupled concentrative transporter and thus, a better candidate to deplete extracellular adenosine stores when required. In rat hepatoma FAO and liver parenchymal cells activation of A1 receptor leads to a transient increase in CNT2-related activity. This activation is sensitive to glucose levels and dependent on the opening of the energy sensitive Katp channels [52] . In intestinal IEC6 cells, extracellular adenosine transported via CNT2 acts as an activator of the AMP-dependent kinsase (AMPK), which is a key modulator of intracellular energy metabolism [53] . These results suggest that extracellular adenosine, through CNT2 function, can modulate the intracellular energy balance by a mechanism that bypasses the classical energy producing/consuming pathways and it is also apparently independent of the purinergic control.
PHARMACOLOGICAL RELEVANCE OF NUCLEO-SIDE TRANSPORTERS
There is no evidence of NTs being implicated in the pathogenesis of any human disease. However, NTs have a clinical significance that can be viewed in several ways. Firstly, NTs are responsible for the cellular uptake of currently used anticancer nucleoside-derived drugs. Thus, expression of these transporters in cancer cells is necessary for their cytotoxicity. Secondly, distribution of NTs in absortive and secretory organs may determine nucleoside analog pharmacokinetics and toxicological properties. And finally, equilibrative nucleoside transporters themselves could serve as drug targets. ENT inhibitors such as dipyridamole and dilazep have long been used as vasodilatory drugs in the treatment of heart and vascular diseases.
CARDIOVASCULAR DRUGS
It is well-documented that adenosine has important cardiovascular effects and presents a cardioprotective value during ischaemic insult or increased myocardial workload [54, 55] . Thus, cardiac NTs could regulate such responses by modulating extracellular adenosine levels. Cardiomyocytes express high levels of all 4 ENTs, whereas CNT2 appears to be the only concentrative NT expressed in myocytes [9] . In fact, ENT inhibitors dilazep, draflazine and dipyridamole produce a clinically relevant vasodilatory effect in the coronary vasculature, as they restrict adenosine uptake and, thus, enhance extracellular concentrations of the nucleoside [7, 56] . In the ischaemic heart, such inhibitors have demonstrable beneficial effects on regional myocardial function [57] . Inhibition of nucleoside uptake into endothelial cells using draflazine substantially increases and prolongs the cardiovascular effects of adenosine [58] . Infusion of the ENT inhibitor R-75231 before coronary artery occlusion in pigs enhances postischaemic recovery of function and reduced infarct size [59] . In the presence of coronary atherosclerosis, dipyridamole produces greater increase in flow in normal vessels compared with diseased vessels, because the latter exhibit less vasodilation by adenosine [60] . In addition to causing vasodilation, dipyridamole can also inhibit platelet aggregation and proliferation of vascular smooth muscle cells [61] .
Anticancer and Antiviral Drugs
Several nucleoside-derivatives are currently used in antiviral and antitumoral therapies. These compounds show slight structural modifications with respect to natural nucleosides and retain most of the metabolic properties of parent compounds. Thus, NTs should be responsible for the translocation of these drugs.
Both pyrimidine and purine nucleoside analogs are currently used clinically as anticancer drugs. The pyrimidine analogs most frequently used are cytarabine, gemcitabine and capecitabine, a pro-drug of 5-fluorouracil, with the nucleoside derivative 5'-DFUR as its immediate precursor. The purine analogs used are cladribine and fludarabine, although new derivatives have been recently developed [62] . Pharmacological profiles for ENTs and CNTs for these compounds have been obtained by combining substrate flux measurements, cross-inhibition studies and electrophysiology ( Table  2) . As for their natural substrates, hENT1 and hENT2 show broad substrate selectivity but Km values higher than those reported for CNTs [63] . hCNT3 seems to be the best drug transporter among NT proteins because it can translocate most of the pyrimidine and purine nucleoside analogs with high affinities [16, 32] . hCNT1 is a high-affinity transporter for pyrimidine derivatives [15, 64] , whereas CNT2, which is a purine nucleoside carrier protein, can transport clofarabine but it does not take up the adenosine derivatives fludarabine and cladribine [65, 66] .
Zidovudine (AZT), stavudine (d4T), lamivudine (3tC), zalcitabine (ddC) and didanosine (ddI) are nucleoside derivatives frequently used in HIV therapy. In contrast to anticancer drugs, these compounds can interact with NTs but in most cases they are not suitable substrates ( Table 2 ) [67] . The most common antiviral AZT is translocated by hCNT1, hCNT3 and hENT2 but not by hENT1, although AZT can inhibit ENT1-mediated nucleoside transport [12, [68] [69] [70] . However, the apparent affinity values are lower than those described for anticancer drugs, such as gemcitabine ( Table  2) . The difference between antitumoral and antiviral drugs is that the latter lack the 3'hydroxyl group of the sugar. Analysis of substrate structural determinants demonstrates that this residue is relevant for nucleoside recognition and translocation [68, 71, 72] , indicating that a slight structural modifications provokes a dramatic change in transportability.
In vitro studies have demonstrated that nucleoside transporters are necessary for antitumoral nucleoside analogs entry into the cells [73] [74] [75] . However, as indicated above, NTs have different pharmacological profiles. Thus, the amount or even the mere presence or absence of a particular transporter protein might determine drug sensitivity. Initially, the putative role of NT function in drug uptake, bioavailability and cytotoxicity was addressed in cell culture models. Comparison of gemcitabine sensitivity among cell lines with or without NT-related activity demonstrated that gemcitabine requires functional NTs to cause cytotoxicity [75] . Heterologous expression of hCNT1 in Chinese hamster ovary cells increases cell sensitivity to 5'-DFUR. Moreover, this sensitization is still retained when endogenous ENTs are blocked using dipyridamole, thus suggesting that the retention of a high-affinity concentrative transporter might be a determinant of cytotoxicity by itself [64] . Similar results have been obtained in the human breast cancer cell line MCF-7 [76] . The presence of hCNT2 activity also conferred sensitivity to fluoropyrimidine nucleosides in CEM cells heterologously expressing this NT transporter protein [66] .
Several studies have analyzed the expression of NTs using PCR or antibodies in different tumours demonstrating heterogeneity in the expression of these transporters. hENT1 protein has been analyzed in breast tumors, demonstrating heterogeneity of hENT1 staining in a cohort of 33 patients, 4 of them apparently lacking hENT1 protein expression [77] . In a high throughput analysis of gynaecologic tumours using immunohistochemistry it was found heterogeneity in the expression of hENT1, hENT2 and hCNT1, being the latter the most frequently lost protein. Interestingly, hCNT1 loss associated with particular histological subtypes characterized by poor prognosis [49] . Variability in the expression of NT has also been assessed in several lymphoproliferative diseases [78] [79] [80] . These results together with in vitro data demonstrating the importance of NTs in cell sensitivity to nucleoside analogs, suggest a clinical correlation between NT expression and drug sensitivity.
Initially, most of the clinical studies focused on the hENT1 transporter, probably because its abundance could be measured, in the absence of suitable antibodies, by determining the high-affinity binding sites for NBTI or the fluorescent nucleoside derivative SAENTA. This was done mostly in lymphoproliferative malignancies, as these diseases allow the simultaneous measurement of the ex vivo sensitivity to drugs used in patient therapy. Several studies have reported a correlation between hENT1 expression and cytarabine sensitivity in acute myeloid and lymphoid leukaemia (AML and ALL) [81] [82] [83] . In chronic lymphocitic leukaemia (CLL) a significant correlation between fludarabine uptake via ENT carriers, hENT2 protein expression and ex vivo sensitivity was detected [78, 84] . Morever, CLL patients with elevated hCNT3 expression in their CLL cells experienced a low complete response rate to fludarabine therapy [85] . On the other hand, in mantle cell lymphoma, hENT1 expression correlated with gemcitabine but not with fludarabine triggered cytotoxicity [79] .
Studies comparing NT protein profiles with clinical parameters relevant to outcome and survival in solid tumours are still scarce, due to the difficulty to obtain samples and the need of suitable antibodies. The absence of hENT1 protein is associated with reduced survival in gemcitabine-treated patients suffering from pancreatic adenocarcinoma [86] . A correlation between hENT1-related mRNA and gemcitabine sensitivity has also been detected when analyzing samples S: substrate (when it is known, apparent Km value is given); NT: not substrate; NT a : not substrate but inhibitor; inh: drugs tested as inhibitors but not as substrate. from 102 pancreas cancer patients [87] . Breast cancer patients under CMF (ciclophosphamide/methotrexate/5-fluorouracil) therapy after surgery, were shown to have a higher risk of relapse and reduced disease-free survival if their tumours expressed high levels of hCNT1 [88] .
In summary, nucleoside transporter expression in human tumours is variable and increasing experimental evidence supports the view that NTs might play a crucial role in nucleoside-derived drug bioavailability and responsiveness. This would eventually lead to the analysis of NT expression patterns as suitable predictors of response to therapy and patient outcome. However, interindividual variability has also been reported suggesting that amounts and distribution of NTs in other tissues, as in absortive and secretory organs, may determine nucleoside analog pharmacokinetics and toxicological properties.
POLYMORPHIC VARIANTS OF NTS
Genetic polymorphisms in transporter proteins might contribute to interindividual differences, not only in the primarily physiological role these proteins play but also in the sensitivity, absorption, distribution and excretion of an increasing number of drugs. Moreover, analysis of polymorphic variants can provide novel insights into the structurefunction relationship of these proteins.
Extensive progress has been made so far in the analysis of particular polymorphisms of drug transporters and metabolic enzymes, such as P-glycoprotein and cytochrome P450, and their effects on drug extrusion and metabolism rates of anticancer drugs [89, 90] . However, a renewed interest in polymorphic genes related to drug transport and metabolism has arised in the recent years. In some cases, these studies demonstrated that the analysis of the haplotype rather than the association with single nucleotide polymorphisms (SNPs) provides the most appropriate interpretation of pharmacogenetic data. For example, presence of haplotype*3 in cytidine deaminase, the enzyme that converts gemcitabine to its inactive metabolite, decreases the clearance of gemcitabine and increases the incidence of neutropenia when patients are coadministered platinum-containing drugs or fluorouracil [91] . Similarly, some haplotypes in the CYP2C8 gene affect paclitaxel pharmacokinetic parameters [92] .
Concerning drug transporters, genetic variants have been reported for several SLC gene families. A comprehensive list of some of these variants is available at www.pharmgkb.org. Although gene sequence variability has been detected in defined ethnically diverse populations, only a few of them have been functionally characterized to date. In some cases this has led to the detection of some biologically relevant variants. For example, individuals carrying the OATP-C *15 allele (Asp130Ala174) show reduced total and non-renal clearance of pravastatin as compared to subjects homozygous for the OATP-C*1b (Asp130Val174) allele [93] .
Although some variants have been identified in SLC28 and SLC29 genes, only a few of them have been comprehensively well characterized in vitro. Several genetic variants have been described for hENT1 but they do not seem to affect hENT1-related biological function significantly [94, 95] . However, some haplotypes identified at the hENT1-encoding gene (SLC29A1) promoter appear to influence its transcriptional activity and eventually alter cytarabine chemosensitivity [96] . In hENT2-encoding gene (SLC29A2), all variants analyzed so far were able to transport inosine, with the exception of ENT2-845-846, which results in a frameshift mutation that prematurely truncates the protein [97] . A total of 58 single nucleotide polymorphisms have been identified in the hCNT1 encoding gene (SLC28A1). All the nonsynonymous variants but two were able to translocate thymidine. These non functional hCNT1 proteins were hCNT1-Ser546Pro, a rare variant that results in the change of an evolutionarily conserved serine located in putative transmembrane domain 12, and hCNT1-1153del, a variant that presumably results in a truncated protein. Moreover, although the uptake of thymidine is similar to that reported for the reference hCNT1, the variant CNT1-Val189Ile presents a reduced affinity for gemcitabine. Interestingly, this is a common variant found at a frequency of 26% [98] . The genetic variants described for hCNT2 do not seem to alter function, except the variant hCNT2-Phe355Ser which exhibits a decrease in uridine uptake [99] . This is consistent with observations [100] indicating that the region where Phe355 is situated could be involved in substrate recognition. Recently, new hCNT2 variants have been identified, all of them but Glu385Lys can transport various hCNT2 substrates [101] . Similarly, among the new variants recently identified for hCNT3, only 10 resulted in altered protein sequence, although the variant Gly367Arg was the only one showing altered biological function (reduced transport activity) [102, 103] . A novel and highly interesting non-synonymous variant of hCNT3, Cys602Arg, has recently been described. This protein shows reduced activity, apparently due to the incorporation of a charged residue in putative transmembrane domain 13, which seems to impair the binding of one of the two Na + ions necessary for efficient translocation of nucleosides by hCNT3 [104] .
Compared with other transporter gene families, structure variability of NTs appears to be relatively constrained and few polymorphisms with functional implications have been identified so far. However, some of them show relatively high allele frequencies and are candidate genes to explain nucleoside homeostasis variability, impaired adenosine signalling events, and variable nucleoside-derived drug pharmacokinetics.
